ACT Brief: Smarter Study Planning, New AML Approval, and Biomarker Gaps in Cancer Care

 In today’s ACT Brief, we look at how real-world data and AI are helping prevent costly study rescue, review the FDA’s approval of a first-in-class menin inhibitor for NPM1-mutated AML, and explore new insights on closing biomarker-testing gaps in oncology.